China, Shanghai — Recently, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort"), a subsidiary of MicroPort Scientific Corporation (00853.HK),^®MicroPort announced that, as of the end of September 2025, the cumulative global shipments and implantations of its full series of coronary stent systems have both surpassed the milestone of "10 million sets." Among them, overseas cumulative sales account for approximately 20% and are showing a rapid growth trend.

By continuously深耕ing the local market and expanding global business, as of now, MicroPort^®Coronary stents have been deployed in over 4,000 hospitals across 34 provincial administrative regions in China. Among these, through the "Feiyan Project," interventional treatment technology has reached more than 1,300 county-level hospitals. Since its market launch in 2004, it has consistently ranked first in market share nationwide, serving over 6 million patients cumulatively. Currently, its overall market share in China stands at 43%.

On the international stage, MicroPort^®The footprint of coronary products has spread to more than 3,000 hospitals across nearly 90 countries and regions. In recent years, MicroPort^®Key breakthroughs and impressive performance have been achieved in multiple strategic and emerging markets, including Europe, Asia, South America, and North America: the compound annual growth rate of sales from 2021 to 2024 reached 35%, with the sales volume of the DES product portfolio increasing by approximately 300%. As overseas operations continue to expand, their contribution to coronary stent sales has also been increasing year by year, rising from 15% in 2021 to nearly 30% in 2024. The expected shipment volume for 2025 alone is close to 400,000 units.

“The growth of these data is attributed to MicroPort.^®Strong brand influence and solid product performance are also due to the 'self-owned global promotion platform + agent channel'.’The geographical breadth breakthrough brought by the hybrid strategy." MicroPort^®Ms. Liang Min, Head of Overseas Commercial, emphasized, "MicroPort^®Will continue to expand overseas core markets, while actively promoting product iteration and the implementation of new technologies in overseas markets."Currently, Firehawk^®Full Iteration to Firehawk in the High-end Market^® Liberty, the intravascular shock wave catheter system, OCT optical coherence tomography system, bioresorbable scaffolds, and other new products are also accelerating their rollout.

As MicroPort^®The earliest product series under the medical sector, the coronary product family started in 1998 when the company was founded. In 2004, the company launched China's first drug-eluting stent, Firebird™, which gained high clinical recognition in the same year it was marketed and captured 40% of the Chinese market share. From 2009 to 2014, the iterative product Firebird2...^®/Firebird™ to the world's first clinically used Targeted Drug-Eluting Stent Firehawk^®/FireHawk^®, MicroPort^®Spent 5 years achieving a transformation from technology follower to technology leader in the coronary stent field, and will continue to launch the new generation of bioresorbable scaffold Firesorb in 2024.^®/Fire Ibis^®。

Today's MicroPort^®The Coronary Product Family, Including Five Stent Systems That Meet Global Clinical Needs and Patient-Specific Requirements: Firesorb^®/Fire Ibis^®Bioabsorbable支架、Firehawk^®/FireHawk^®Drug-Eluting Stent, FireCondor^®/Fire God Eagle^®Drug-Eluting Stent (Overseas Product Registration Name: Firehawk)^® Liberty ）、Firebird2^®/Firebird™ Drug-Eluting Stent and Firebird Pro+^®/Firebird Pro+™ Drug-Eluting Stent, while also gradually building a comprehensive solution for the treatment of coronary artery disease that integrates “passive devices + active equipment + imaging detection products”: China's first coronary rotational atherectomy system, China's first batch of OCT optical coherence tomography imaging equipment, and intravascular shockwave catheter systems have successively been launched. The coronary intravascular piezoelectric guidewire system is expected to be approved for marketing this year, and other products under development, such as the coronary sinus balloon counterpulsation system, will also quickly advance into clinical use. Through persistent innovation and investment, MicroPort continues to iterate and launch innovative products to protect patients with coronary heart disease worldwide.

On August 31 this year, the top journal *The New England Journal of Medicine* and the European Society of Cardiology Congress simultaneously released the TARGET-FIRST study results: For low-risk acute myocardial infarction (AMI) patients, Firehawk^®/FireHawk^®Stents can shorten the Dual Antiplatelet Therapy (DAPT) course from 12 months to 1 month, not only without increasing the risk of ischemia but also reducing the risk of bleeding complications by 54%. This exciting research finding has drawn significant attention from authoritative medical organizations such as the American College of Cardiology and the American Heart Association. In fact, as early as 2018, studies surrounding the Firehawk...^®/Firehawk^®Another clinical study, TARGET AC, was featured in the top journal *The Lancet* for addressing the challenge of "late stent thrombosis." These research achievements not only established a comprehensive foundation for Firehawk.^®/FireHawk^®The evidence-based medicine system has also enabled Chinese medical device companies to gain widespread recognition and respect in the international market and academic field.

As of now, the TARGET series of "Firehawk" has been carried out in more than 200 medical centers worldwide, with over 17,500 patients enrolled cumulatively; while "Firebird" has been on the market for a short time, and its FUTURE series of three studies have already completed 3 to 5 years of follow-up for over 1,400 patients.

MicroPort^®Dr. Yue Bin, President of Coronary Division, said: "10 million stents, each one carries the patient's desire for life, the doctor's commitment to professionalism, and MicroPort^®Coronary's Commitment and Responsibility to Society. This will be a new starting point. The company will not only continue to drive the iterative innovation of cardiac stents but also aim for more 'tens of millions' level targets across its full range of product lines, including passive devices, active equipment, and imaging detection products. At the same time, it will make strides in intelligent surgery, as well as telemedicine and home healthcare, striving to become a global leader in technological innovation and commercialization capabilities within the coronary field.

MicroPort^®Chief Marketing Officer of Greater China, MicroPort^®Mr. Jiang Lei, Chairman of MicroPort, stated: "This milestone marks a solid leap forward in China's medical device independent innovation from 'catching up' to 'leading.' Today, this innovative momentum has extended to business areas such as surgical robots, heart valves, electrophysiology, and rhythm management."^®"We will continue to work towards more 'quantum' milestones. In the future, the group will join hands with global partners to promote the efficient development of each sector through a network of multiple connections and high-efficiency collaboration, broaden commercial reach, and faithfully fulfill the inspiring mission of 'providing life-extending and life-enhancing solutions that are accessible and affordable for hundreds of millions of patients.'"